AtriCure, Inc. (ATRC)
NASDAQ: ATRC · Real-Time Price · USD
35.38
-0.28 (-0.79%)
Sep 5, 2025, 4:00 PM - Market closed
AtriCure Revenue
AtriCure had revenue of $136.14M in the quarter ending June 30, 2025, with 17.09% growth. This brings the company's revenue in the last twelve months to $499.95M, up 16.28% year-over-year. In the year 2024, AtriCure had annual revenue of $465.31M with 16.55% growth.
Revenue (ttm)
$499.95M
Revenue Growth
+16.28%
P/S Ratio
3.35
Revenue / Employee
$384,574
Employees
1,300
Market Cap
1.76B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 465.31M | 66.06M | 16.55% |
Dec 31, 2023 | 399.25M | 68.87M | 20.84% |
Dec 31, 2022 | 330.38M | 56.05M | 20.43% |
Dec 31, 2021 | 274.33M | 67.80M | 32.83% |
Dec 31, 2020 | 206.53M | -24.28M | -10.52% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ATRC News
- 17 days ago - AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference - Business Wire
- 5 weeks ago - AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025 - Business Wire
- 5 weeks ago - AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 7 weeks ago - AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention - Business Wire
- 2 months ago - AtriCure to Announce Second Quarter 2025 Financial Results - Business Wire
- 3 months ago - AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Business Wire
- 4 months ago - AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript - Seeking Alpha